Tokyo Tape
Sign in
← Oncolys BioPharma

Annual report

4588.TEDINET S100PNBN
Period2017-01-01 → 2017-12-31
Filed2022-11-17
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed

Amends S100CP6F.

Key figures · 78
MetricValuePeriodScopeSource row
Revenue¥229m2017-01-01 → 2017-12-31StandaloneNet sales
Revenue¥178m2016-01-01 → 2016-12-31StandaloneNet sales
Revenue¥121m2015-01-01 → 2015-12-31dStandaloneNet sales (5-year summary)
Revenue¥29m2014-01-01 → 2014-12-31dStandaloneNet sales (5-year summary)
Revenue¥1m2013-01-01 → 2013-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.1bn2017-01-01 → 2017-12-31StandaloneOperating income
Operating income−¥861m2016-01-01 → 2016-12-31StandaloneOperating income
Ordinary income−¥1.1bn2017-01-01 → 2017-12-31StandaloneOrdinary income
Ordinary income−¥864m2016-01-01 → 2016-12-31StandaloneOrdinary income
Ordinary income−¥855m2015-01-01 → 2015-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥726m2014-01-01 → 2014-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥625m2013-01-01 → 2013-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.1bn2017-01-01 → 2017-12-31StandaloneIncome before income taxes
Profit before tax−¥928m2016-01-01 → 2016-12-31StandaloneIncome before income taxes
Net income−¥1.1bn2017-01-01 → 2017-12-31StandaloneProfit loss
Net income−¥931m2016-01-01 → 2016-12-31StandaloneProfit loss
Net income−¥857m2015-01-01 → 2015-12-31dStandaloneNet income loss (5-year summary)
Net income−¥739m2014-01-01 → 2014-12-31dStandaloneNet income loss (5-year summary)
Net income−¥636m2013-01-01 → 2013-12-31dStandaloneNet income loss (5-year summary)
Total assets¥3.5bnat 2017-12-31StandaloneAssets
Total assets¥3.1bnat 2016-12-31StandaloneAssets
Total assets¥4.0bnat 2015-12-31dStandaloneTotal assets (5-year summary)
Total assets¥5.0bnat 2014-12-31dStandaloneTotal assets (5-year summary)
Total assets¥5.7bnat 2013-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥594mat 2017-12-31StandaloneLiabilities
Total liabilities¥523mat 2016-12-31StandaloneLiabilities
Net assets / equity¥2.9bnat 2017-12-31StandaloneNet assets
Net assets / equity¥2.6bnat 2016-12-31StandaloneNet assets
Net assets / equity¥3.5bnat 2015-12-31dStandaloneNet assets
Net assets / equity¥4.4bnat 2014-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥5.1bnat 2013-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥2.9bnat 2017-12-31StandaloneCash and deposits
Cash and deposits¥2.6bnat 2016-12-31StandaloneCash and deposits
Cash & equivalents¥1.9bnat 2017-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.4bnat 2016-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2015-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥1.2bnat 2014-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥5.4bnat 2013-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.1bn2017-01-01 → 2017-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥903m2016-01-01 → 2016-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥756m2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥814m2014-01-01 → 2014-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥599m2013-01-01 → 2013-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow¥132m2017-01-01 → 2017-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥257m2016-01-01 → 2016-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥1.8bn2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥3.4bn2014-01-01 → 2014-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥110m2013-01-01 → 2013-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.5bn2017-01-01 → 2017-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥6m2016-01-01 → 2016-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥120m2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥233,0002014-01-01 → 2014-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥5.4bn2013-01-01 → 2013-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-106.232017-01-01 → 2017-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-101.182016-01-01 → 2016-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-93.352015-01-01 → 2015-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-80.552014-01-01 → 2014-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-94.332013-01-01 → 2013-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥263.54at 2017-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥283.43at 2016-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥381.27at 2015-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥476.03at 2014-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥561.17at 2013-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio82.9%at 2017-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio82.7%at 2016-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio87.2%at 2015-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio87.2%at 2014-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio89.3%at 2013-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued11,086,000at 2017-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,234,600at 2016-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,183,800at 2015-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,183,200at 2014-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,076,900at 2013-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees29at 2017-12-31StandaloneNumber of employees
Employees30at 2016-12-31StandaloneNumber of employees
Employees29at 2015-12-31dStandaloneNumber of employees
Employees28at 2014-12-31dStandaloneNumber of employees
Employees22at 2013-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 24
SegmentItemPeriodValue
Reconciling Itemsreconcilingdepreciation2017-01-01 → 2017-12-31¥1m
Reconciling Itemsreconcilingsegment profit2017-01-01 → 2017-12-31−¥537m
Diagnostic Divisionreportable segmentrevenue2017-01-01 → 2017-12-31¥33m
Diagnostic Divisionreportable segmentrevenue external2017-01-01 → 2017-12-31¥33m
Diagnostic Divisionreportable segmentsegment profit2017-01-01 → 2017-12-31−¥104m
Pharmaceutical Divisionreportable segmentrevenue2017-01-01 → 2017-12-31¥197m
Pharmaceutical Divisionreportable segmentrevenue external2017-01-01 → 2017-12-31¥197m
Pharmaceutical Divisionreportable segmentsegment profit2017-01-01 → 2017-12-31−¥438m
Total Of Reportable Segments And Otherssegment totalrevenue2017-01-01 → 2017-12-31¥229m
Total Of Reportable Segments And Otherssegment totalrevenue external2017-01-01 → 2017-12-31¥229m
Total Of Reportable Segments And Otherssegment totalsegment profit2017-01-01 → 2017-12-31−¥542m
Reconciling Itemsreconcilingdepreciation2016-01-01 → 2016-12-31¥4m
Reconciling Itemsreconcilingsegment profit2016-01-01 → 2016-12-31−¥438m
Diagnostic Divisionreportable segmentdepreciation2016-01-01 → 2016-12-31¥11m
Diagnostic Divisionreportable segmentrevenue2016-01-01 → 2016-12-31¥60m
Diagnostic Divisionreportable segmentrevenue external2016-01-01 → 2016-12-31¥60m
Diagnostic Divisionreportable segmentsegment profit2016-01-01 → 2016-12-31−¥105m
Pharmaceutical Divisionreportable segmentrevenue2016-01-01 → 2016-12-31¥119m
Pharmaceutical Divisionreportable segmentrevenue external2016-01-01 → 2016-12-31¥119m
Pharmaceutical Divisionreportable segmentsegment profit2016-01-01 → 2016-12-31−¥318m
Total Of Reportable Segments And Otherssegment totaldepreciation2016-01-01 → 2016-12-31¥11m
Total Of Reportable Segments And Otherssegment totalrevenue2016-01-01 → 2016-12-31¥178m
Total Of Reportable Segments And Otherssegment totalrevenue external2016-01-01 → 2016-12-31¥178m
Total Of Reportable Segments And Otherssegment totalsegment profit2016-01-01 → 2016-12-31−¥423m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 712
ItemContextValueUnit
Net salesPrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Net salesPrior1YearDuration_NonConsolidatedMember178313000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember-318238000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember-105058000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember-423296000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember-438014000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember-861311000JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember－JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember11039000JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember11039000JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember4325000JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember15364000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember196552000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember32586000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember229139000JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYearDuration_NonConsolidatedMember229139000JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYearDuration_NonConsolidatedMember－JPY
Net salesCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember196552000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember32586000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember229139000JPY
Net salesCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Net salesCurrentYearDuration_NonConsolidatedMember229139000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember-438213000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember-103521000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember-541734000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember-536655000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember-1078389000JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember－JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember－JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember－JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember_ReconcilingItemsMember1162000JPY
Depreciation segment informationCurrentYearDuration_NonConsolidatedMember1162000JPY
Impairment loss elPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember－JPY
Impairment loss elPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember47353000JPY
Impairment loss elPrior1YearDuration_NonConsolidatedMember_UnallocatedAmountsAndEliminationMember11107000JPY
Impairment loss elPrior1YearDuration_NonConsolidatedMember58461000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書(令和４年11月17日付け訂正報告書の添付インラインXBRL)
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2018-03-30
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第14期(自　平成29年１月１日　至　平成29年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Company name in english cover pageFilingDateInstantOncolys BioPharma Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　浦田　泰生
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目１番28号

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2016-12-31pass rounding
balance sheet identitynon_consolidated 2017-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2015-12-31pass
statement vs summary · net assetsnon_consolidated 2016-12-31pass
statement vs summary · net assetsnon_consolidated 2017-12-31pass
statement vs summary · operating cash flownon_consolidated 2016-01-01/2016-12-31pass
statement vs summary · operating cash flownon_consolidated 2017-01-01/2017-12-31pass
statement vs summary · revenuenon_consolidated 2016-01-01/2016-12-31pass
statement vs summary · revenuenon_consolidated 2017-01-01/2017-12-31pass
statement vs summary · total assetsnon_consolidated 2016-12-31pass
statement vs summary · total assetsnon_consolidated 2017-12-31pass